See more : PT Northcliff Citranusa Indonesia Tbk (SKYB.JK) Income Statement Analysis – Financial Results
Complete financial analysis of Panacea Life Sciences Holdings, Inc. (PLSH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Panacea Life Sciences Holdings, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Goliath Resources Limited (GOT.V) Income Statement Analysis – Financial Results
- Dynemic Products Limited (DYNPRO.NS) Income Statement Analysis – Financial Results
- Healwell AI Inc. (AIDX.TO) Income Statement Analysis – Financial Results
- Coca-Cola HBC AG (EEE.AT) Income Statement Analysis – Financial Results
- Trian Investors 1 Limited (TI1.L) Income Statement Analysis – Financial Results
Panacea Life Sciences Holdings, Inc. (PLSH)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.panacealife.com
About Panacea Life Sciences Holdings, Inc.
Panacea Life Sciences Holdings, Inc., a seed to sale cannabinoid and nutraceutical manufacturer and research company, develops and produces natural pharmaceutical alternatives for consumers and pets. The company manufactures and sells softgels, gummies, tinctures, sublingual tablets, cosmetics, and other topicals. It is also involved in the personal protection equipment (PPE) business, including importing and selling PPE hand sanitizers and masks, as well as white label and contract manufacturing sales to other cannabinoid companies, raw material sales, and tolling arrangements. The company was incorporated in 2008 and is headquartered in Greenwood Village, Colorado.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
---|---|---|---|---|---|---|---|---|---|
Revenue | 2.38M | 1.63M | 2.06M | 9.02M | 345.68K | 0.00 | 0.00 | 0.00 | 213.00 |
Cost of Revenue | 6.47M | 1.23M | 1.52M | 7.02M | 2.05M | 0.00 | 0.00 | 0.00 | 20.63K |
Gross Profit | -4.09M | 396.47K | 540.58K | 2.00M | -1.70M | 0.00 | 0.00 | 0.00 | -20.41K |
Gross Profit Ratio | -171.48% | 24.37% | 26.25% | 22.15% | -491.92% | 0.00% | 0.00% | 0.00% | -9,583.10% |
Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 22.10K | 300.00K | 356.08K | 369.34K | 77.34K |
General & Administrative | 1.44M | 1.09M | 1.52M | 2.81M | 731.26K | 0.00 | 0.00 | 0.00 | 0.00 |
Selling & Marketing | 17.95K | 209.25K | 377.92K | 638.63K | 254.87K | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 1.46M | 1.09M | 1.52M | 2.81M | 8.95M | 2.14M | 1.64M | 1.23M | 289.69K |
Other Expenses | 0.00 | 4.70M | 4.56M | 4.45M | 4.12M | 2.14M | 2.77M | 1.23M | 291.31K |
Operating Expenses | 2.37M | 5.79M | 6.08M | 7.26M | 8.97M | 2.44M | 2.00M | 1.60M | 367.03K |
Cost & Expenses | 7.93M | 7.03M | 7.60M | 14.28M | 11.02M | 2.44M | 2.00M | 1.60M | 368.66K |
Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 683.24K | 2.05M | 1.11M | 1.51M | 479.11K | -464.47K | -68.57K | 0.00 | 0.00 |
Depreciation & Amortization | 1.71M | 1.73M | 1.74M | 1.69M | 892.30K | 405.17K | 52.80K | 22.82K | 1.63K |
EBITDA | -4.75M | -5.36M | -1.94M | -2.03M | -8.65M | -3.48M | -3.12M | -1.60M | -356.35K |
EBITDA Ratio | -199.02% | -209.44% | -210.66% | -51.69% | -2,829.33% | 0.00% | 0.00% | 0.00% | -172,211.27% |
Operating Income | -5.55M | -5.40M | -5.54M | -5.26M | -10.67M | -2.44M | -2.00M | -1.60M | -368.44K |
Operating Income Ratio | -232.55% | -331.81% | -269.00% | -58.31% | -3,087.46% | 0.00% | 0.00% | 0.00% | -172,976.53% |
Total Other Income/Expenses | -2.47M | -3.49M | 1.15M | 26.01K | 653.94K | -1.90M | -1.86M | -5.53K | 10.46K |
Income Before Tax | -8.02M | -9.14M | -4.78M | -5.23M | -10.02M | -4.34M | -3.86M | -1.60M | -357.98K |
Income Before Tax Ratio | -336.08% | -561.94% | -232.20% | -58.02% | -2,898.29% | 0.00% | 0.00% | 0.00% | -168,064.32% |
Income Tax Expense | 0.00 | 1.96M | 1.34M | 1.76M | -537.47K | -161.14K | -52.52K | -22.82K | 3.00 |
Net Income | -8.02M | -11.10M | -6.12M | -6.99M | -9.48M | -4.34M | -3.86M | -1.60M | -357.98K |
Net Income Ratio | -336.08% | -682.14% | -297.35% | -77.57% | -2,742.81% | 0.00% | 0.00% | 0.00% | -168,064.32% |
EPS | -0.48 | -0.75 | -0.34 | -0.41 | -7.83 | -25.49 | -25.47 | -18.68 | -156.61 |
EPS Diluted | -0.48 | -0.75 | -0.34 | -0.41 | -7.83 | -25.49 | -25.47 | -18.68 | -156.61 |
Weighted Avg Shares Out | 16.63M | 14.86M | 17.82M | 16.92M | 1.21M | 170.14K | 151.55K | 85.81K | 2.29K |
Weighted Avg Shares Out (Dil) | 16.63M | 14.86M | 17.82M | 16.92M | 1.21M | 170.14K | 151.55K | 85.81K | 2.29K |
Panacea Life Sciences and Sky Wellness Enter Agreement for Licensing, Marketing, Supply and Development of Sky Wellness CBD Products
Panacea Life Sciences Holdings, Inc. Completes Acquisition of N7 Enterprises With Eight Natural Health and Wellness Retail and One Distribution Center Locations in the Tampa, Florida area
Panacea Life Sciences Holdings, Inc. Continues Growth Trajectory with Acquisition of the PÜR LIFE Medical Franchise
Panacea Life Sciences Holdings, Inc. Celebrates National CBD Day (August 8th) By Shifting To An “Everyday Low Pricing Model” To Meet Customer Needs
Panacea Life Sciences Holdings, Inc. Continues Pursuit of High Growth Health and Wellness Products with Acquisition of Sierra Sage, LLC and Halucenex from Melodial Global Health (formerly Creso Pharma Limited)
Panacea Life Sciences Holdings, Inc. Announces CBD/CBG Clinical Trial Findings for the Management of Irritable Bowel Symptoms
Panacea Life Sciences Holdings, Inc. Chief Scientific Officer, Dr. James Baumgartner, is Featured on The Stock Day Podcast
Panacea Life Sciences Holdings, Inc. Chief Scientific Officer, Dr. James Baumgartner, is Featured on The Stock Day Podcast
Panacea Life Sciences Holdings, Inc. Enters Into Agreement to Natural Health and Wellness Chain of Retail Locations in Tampa, Florida
Panacea Life Sciences Holdings, Inc. Adopts Diversification Plan: Vegan, Organic, Nutraceuticals, Alternative Health and Wellness Products and Investigative Research Plans for Psylocibin and other Psychedelics.
Source: https://incomestatements.info
Category: Stock Reports